FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4322769596> ?p ?o ?g. }

• W4322769596 endingPage "15" @default.
• W4322769596 startingPage "P6" @default.
• W4322769596 abstract "Abstract Background. Because of its high metastatic potential, inflammatory breast cancer (IBC) is the most lethal and aggressive form of breast cancer. We previously demonstrated that Myristoylated Alanine-Rich C Kinase Substrate (MARCKS) protein overexpression was associated with shorter metastasis-free survival (MFS) in IBC patients, but not in non-IBC (nIBC) patients. However, the mechanism of action of MARCKS and its particular association to poorer outcome in IBC compared to nIBC are poorly understood. Methods. We evaluated in vitro the inhibitory effect of MPS (MARCKS phosphorylation site domain), a peptide targeting MARCKS phosphorylation site domain (PSD) in single and in combination with paclitaxel treatment, on cell proliferation and cell motility in two cell lines of different phenotype (SUM149 for IBC and MDA-MB-231 for nIBC), as well as its distinct molecular mechanisms of action. We also assessed the clinical relevance of the protein expression of MARCKS and phosphatase and tensin homolog (PTEN) in a large series of IBC vs. nIBC patients. Results. In vitro, the treatment with MPS peptide impaired cell proliferation, migration, and invasion in SUM149 compared to MDA-MB-231 cells. More important, MARCKS inhibition increased paclitaxel sensitivity when using combination therapy in SUM149 cells compared to MDA-MB-231 cells. Interestingly, we could partially explain this specific inhibitory effect in IBC cells using western blot: MARCKS inhibition in single and in combination induced up and downregulation of the PTEN/AKT signaling pathway respectively in IBC compared to nIBC cells. Importantly, a negative correlation of MARCKS and PTEN was only found in the clinical IBC samples (180 patients) compared to nIBC samples (355 patients). More importantly, the group of patients with negative MARCKS and positive PTEN protein expression was associated to better 5-year MFS only in IBC patients. Conclusion. These results indicate two major findings: first, the important prognostic value of the negative correlation of MARCKS and PTEN expression in IBC patients, and second the specific role of MARCKS in regulating different downstream pathways and increasing the paclitaxel response in combination treatment in IBC compared to non-IBC. They suggest a potential IBC-specific targetable biomarker, the inhibition of which might impair disease aggressiveness and perhaps enhance patients’ survival. Citation Format: Maroua Manai, Ines Bini, Pascal Finetti, Haifa Bichiou, Carolina Reduzzi, Naziha Ben Hamida, Marc Lopez, Khaled Rahal, Karima Mrad, Mohamed Manai, Massimo Cristofanilli, Hamouda Boussen, Raoudha Doghri, Maher Kharrat, François Bertucci. Targeting MARCKS in inflammatory breast cancer increased paclitaxel sensitivity [abstract]. In: Proceedings of the 2022 San Antonio Breast Cancer Symposium; 2022 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2023;83(5 Suppl):Abstract nr P6-10-15." @default.
• W4322769596 created "2023-03-03" @default.
• W4322769596 creator A5030825526 @default.
• W4322769596 creator A5032451220 @default.
• W4322769596 creator A5032987754 @default.
• W4322769596 creator A5040167291 @default.
• W4322769596 creator A5055645057 @default.
• W4322769596 creator A5061013554 @default.
• W4322769596 creator A5062512216 @default.
• W4322769596 creator A5063626883 @default.
• W4322769596 creator A5067973844 @default.
• W4322769596 creator A5073384497 @default.
• W4322769596 creator A5079179961 @default.
• W4322769596 creator A5081259533 @default.
• W4322769596 creator A5081278609 @default.
• W4322769596 creator A5090186321 @default.
• W4322769596 creator A5091721810 @default.
• W4322769596 date "2023-03-01" @default.
• W4322769596 modified "2023-09-26" @default.
• W4322769596 title "Abstract P6-10-15: Targeting MARCKS in inflammatory breast cancer increased paclitaxel sensitivity" @default.
• W4322769596 doi "https://doi.org/10.1158/1538-7445.sabcs22-p6-10-15" @default.
• W4322769596 hasPublicationYear "2023" @default.
• W4322769596 type Work @default.
• W4322769596 citedByCount "0" @default.
• W4322769596 crossrefType "journal-article" @default.
• W4322769596 hasAuthorship W4322769596A5030825526 @default.
• W4322769596 hasAuthorship W4322769596A5032451220 @default.
• W4322769596 hasAuthorship W4322769596A5032987754 @default.
• W4322769596 hasAuthorship W4322769596A5040167291 @default.
• W4322769596 hasAuthorship W4322769596A5055645057 @default.
• W4322769596 hasAuthorship W4322769596A5061013554 @default.
• W4322769596 hasAuthorship W4322769596A5062512216 @default.
• W4322769596 hasAuthorship W4322769596A5063626883 @default.
• W4322769596 hasAuthorship W4322769596A5067973844 @default.
• W4322769596 hasAuthorship W4322769596A5073384497 @default.
• W4322769596 hasAuthorship W4322769596A5079179961 @default.
• W4322769596 hasAuthorship W4322769596A5081259533 @default.
• W4322769596 hasAuthorship W4322769596A5081278609 @default.
• W4322769596 hasAuthorship W4322769596A5090186321 @default.
• W4322769596 hasAuthorship W4322769596A5091721810 @default.
• W4322769596 hasConcept C11960822 @default.
• W4322769596 hasConcept C195794163 @default.
• W4322769596 hasConcept C2777609662 @default.
• W4322769596 hasConcept C2779549131 @default.
• W4322769596 hasConcept C2780780085 @default.
• W4322769596 hasConcept C502942594 @default.
• W4322769596 hasConcept C62478195 @default.
• W4322769596 hasConcept C71924100 @default.
• W4322769596 hasConcept C75217442 @default.
• W4322769596 hasConcept C86554907 @default.
• W4322769596 hasConcept C86803240 @default.
• W4322769596 hasConcept C95444343 @default.
• W4322769596 hasConceptScore W4322769596C11960822 @default.
• W4322769596 hasConceptScore W4322769596C195794163 @default.
• W4322769596 hasConceptScore W4322769596C2777609662 @default.
• W4322769596 hasConceptScore W4322769596C2779549131 @default.
• W4322769596 hasConceptScore W4322769596C2780780085 @default.
• W4322769596 hasConceptScore W4322769596C502942594 @default.
• W4322769596 hasConceptScore W4322769596C62478195 @default.
• W4322769596 hasConceptScore W4322769596C71924100 @default.
• W4322769596 hasConceptScore W4322769596C75217442 @default.
• W4322769596 hasConceptScore W4322769596C86554907 @default.
• W4322769596 hasConceptScore W4322769596C86803240 @default.
• W4322769596 hasConceptScore W4322769596C95444343 @default.
• W4322769596 hasIssue "5_Supplement" @default.
• W4322769596 hasLocation W43227695961 @default.
• W4322769596 hasOpenAccess W4322769596 @default.
• W4322769596 hasPrimaryLocation W43227695961 @default.
• W4322769596 hasRelatedWork W1599602125 @default.
• W4322769596 hasRelatedWork W1993312761 @default.
• W4322769596 hasRelatedWork W2005620028 @default.
• W4322769596 hasRelatedWork W2744966301 @default.
• W4322769596 hasRelatedWork W2783050518 @default.
• W4322769596 hasRelatedWork W2861688776 @default.
• W4322769596 hasRelatedWork W2900464141 @default.
• W4322769596 hasRelatedWork W3032600770 @default.
• W4322769596 hasRelatedWork W3192317526 @default.
• W4322769596 hasRelatedWork W4319242539 @default.
• W4322769596 hasVolume "83" @default.
• W4322769596 isParatext "false" @default.
• W4322769596 isRetracted "false" @default.
• W4322769596 workType "article" @default.